{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-001392","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2025-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.549836+00:00","generated_at":"2026-05-28T08:11:54.782498+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"CorMedix reports preliminary Q4 2024 net revenue ~$31M, FY ~$43M; Q4 Adj EBITDA >$12M","bullets":["Q4 2024 prelim unaudited net revenue ~$31M; FY 2024 ~$43M; Q4 Adj EBITDA >$12M.","Open purchase orders >$25M for Q1 2025 delivery; shipping DefenCath to all three MDO customers.","LDO implementation targeted H1 2025; aims for 4,000 patients in H2 2025.","Expanded inpatient deployment with Syneos Health in Q1 2025; field team reorganized, some roles eliminated.","FY 2025 opex guidance $72-78M (excl non-cash/one-time); cash & investments ~$52M at Dec 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-001392","json":"https://secwatch.observer/filing/0001213900-25-001392.json","markdown":"https://secwatch.observer/filing/0001213900-25-001392.md","text":"https://secwatch.observer/filing/0001213900-25-001392.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390025001392/0001213900-25-001392-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390025001392/ea0226957-8k_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T08:11:54.782498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}